Document Detail


Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C.
MedLine Citation:
PMID:  14684587     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND AIM: In this study, we compared the efficacy of triple therapy (interferon alfa, ribavirin, and amantadine) with standard therapy (interferon alfa and ribavirin) in treatment naïve patients with chronic hepatitis C virus (HCV).
METHODS: In this prospective, randomised, double blind, placebo controlled, multicentre study, 85 patients (amantadine group) received a three drug regimen of interferon alfa-2b 3 million units three times per week, ribavirin 1000-1200 mg daily in divided doses, and amantadine 100 mg twice daily, and 86 patients (placebo group) received interferon alfa-2b, ribavirin, and identical placebo. Treatment was discontinued at 24 weeks if patients had detectable HCV RNA by polymerase chain reaction (PCR). All patients were followed for 24 weeks after completion of treatment. The primary end point was undetectable HCV-RNA by PCR at 24 weeks (sustained viral clearance) after completion of treatment.
RESULTS: At the end of treatment, HCV RNA clearance was seen in 32.9% of the amantadine group and 38.4% of the placebo group (p=0.3). Sustained virological response was seen in 24.7% of the amantadine group and in 27.9% of the placebo group by intention to treat analysis; response rate was 30.4% and 34.8%, respectively, in those who completed 24 weeks of treatment. Poor response was seen in both groups among cirrhotics, African-Americans, genotype 1, and those with a higher viral load. By multivariate analysis, genotype 1, high viral load, and low serum albumin were the only predictors of poor response. Addition of amantadine to the standard regimen did not result in any unexpected side effects.
CONCLUSION: Response to triple therapy of interferon alfa, ribavirin, and amantadine was similar to standard therapy of interferon alfa and ribavirin. Our results suggest that amantadine has no role in the management of HCV.
Authors:
P J Thuluvath; A Maheshwari; J Mehdi; K D Fairbanks; L L-W Wu; L G Gelrud; M J Ryan; F A Anania; I F Lobis; M Black
Related Documents :
1957127 - Interferon alpha-2b treatment of chronic posttransfusion non-a, non-b/c hepatitis: long...
14961057 - Predicting responsiveness to the treatment of rapid ejaculation with 25 mg clomipramine...
2127787 - A randomized controlled trial of interferon alfa-2b as therapy for chronic non-a, non-b...
17573947 - Double filtration plasmapheresis and interferon combination therapy for chronic hepatit...
20857337 - Comparison of the short-term health-related quality of life in patients with esophageal...
1864057 - Results of total knee arthroplasty using the posterior stabilized condylar prosthesis. ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Gut     Volume:  53     ISSN:  0017-5749     ISO Abbreviation:  Gut     Publication Date:  2004 Jan 
Date Detail:
Created Date:  2003-12-19     Completed Date:  2004-02-26     Revised Date:  2013-06-09    
Medline Journal Info:
Nlm Unique ID:  2985108R     Medline TA:  Gut     Country:  England    
Other Details:
Languages:  eng     Pagination:  130-5     Citation Subset:  AIM; IM    
Affiliation:
Division of Gastroenterology and Hepatology, the Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. pjthuluv@jhmi.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Amantadine / adverse effects,  therapeutic use*
Antiviral Agents / adverse effects,  therapeutic use*
Double-Blind Method
Drug Therapy, Combination
Female
Hepacivirus / isolation & purification
Hepatitis C, Chronic / drug therapy*,  virology
Humans
Interferon-alpha / adverse effects,  therapeutic use
Male
Middle Aged
Prospective Studies
RNA, Viral / analysis
Recombinant Proteins
Ribavirin / adverse effects,  therapeutic use
Risk Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 0/RNA, Viral; 0/Recombinant Proteins; 36791-04-5/Ribavirin; 768-94-5/Amantadine; 99210-65-8/interferon alfa-2b
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha.
Next Document:  Cholesterol synthesis inhibition distal to squalene upregulates biliary phospholipid secretion and c...